HALOHalozyme TherapeuticsSigning up patients
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Hypogonadism, Male
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 100 (planned)
- Started
- Mar 7, 2025
- Main results expected
- Mar 2028
- Fully finished
- Mar 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Increase in testosterone, as evaluated using PK parameters
Measured over: From Enrollment through End of Study Assessments at Week 53
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","statusModule"]}
Trial ID NCT06689085 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC